Palisade Bio Selects Dose Levels For Upcoming Phase 1 Clinical Study Of PALI-2108 For Ulcerative Colitis
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio, Inc. (NASDAQ:PALI) has announced the selection of dose levels for its upcoming Phase 1 clinical study of PALI-2108, a treatment for Ulcerative Colitis. The study is set to commence before the end of the year.
August 08, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Palisade Bio has selected dose levels for its Phase 1 clinical study of PALI-2108 for Ulcerative Colitis, with the study set to begin before the end of the year.
The announcement of dose level selection and the imminent start of Phase 1 clinical trials for PALI-2108 is a significant milestone for Palisade Bio. This progress could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100